Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine
Bioinformation · 31.07.2026 · 22 (07) · 4528-4532
DOI: 10.6026/973206300224528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformation, online erschienen am 31.07.2026. Verfasst von Shivank Shrivastav.
Abstract (Originalsprache)
Globally, 20-25% of the population suffers from dermatophytosis. In India, there is an increase in treatment resistance and an epidemiological shift towards Trichophyton mentagrophytes. This was a prospective study, which randomized 500 patients of dermatophyte infection to either oral itraconazole or terbinafine to find out the rising treatment failure. Tinea cruris was the prevalent diagnosis (37.2%, M:F ratio 2.16:1), with Trichophyton mentagrophytes the commonest pathogen isolated. The clinical resistance of terbinafine was significantly higher than itraconazole (24.4% versus 5.2%, p < 0.0001). With no real mycological resistance found, clinical failure was mainly due to non-compliance (44.6%), diabetes and co-existing onychomycosis. Thus, data show the best first-line therapy is likely itraconazole and dealing with host co-morbidities probably overcomes treatment failure.
Zitieren
APA
Shrivastav, S. (2026). Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine. Bioinformation, 22(07), 4528-4532. https://doi.org/10.6026/973206300224528
Vancouver
Shrivastav S. Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine. Bioinformation. 2026;22(07):4528-4532. doi:10.6026/973206300224528
BibTeX
@article{Shrivastav2026,
author = {Shrivastav, Shivank},
title = {Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine},
journal = {Bioinformation},
year = {2026},
volume = {22},
number = {07},
pages = {4528--4532},
doi = {10.6026/973206300224528}
}
EUVIMED